Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Clinical trial NCT05341583 · RECRUITING

Trial details

NCT number: NCT05341583
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2022-05-24
Primary completion: 2025-06-01
Enrollment: 202

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.